Buloxibutid
Highest phase reached
Early phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Early phase 1
- Drug type
- Small molecule
- Drug name
- Buloxibutid
- Molecular weight
- 475.64
- Structure (SMILES)
- CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1
- buloxibutid
- Buloxibutid
- buloxibutid [INN]
- BULOXIBUTID [USAN]
- buloxibutid inn
- buloxibutid usan
- c 21
- C 21
- C 21 [WHO-DD]
- c 21 who dd
- C-21
- c21
- C21
- compound 21
- Compound 21
- m 24
- M-24
- t2 agonist compound 21
- T2 agonist compound 21
- CAS registry numbers
- 477775-14-7
- ChEMBL ID
- CHEMBL189568
- InChIKey
- XTEOJPUYZWEXFI-UHFFFAOYSA-N
- PubChem compound IDs
- 9804984
- FDA ingredient codes (UNII)
- RC2V4W0EYC
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- compound 21 [PMID: 22802221]
- Type
- Synthetic organic
- Action
- Agonist
- Action type
- Agonist
- Target
- AT2 receptor
- Gene symbol
- AGTR2
- Protein identifier
- P50052
- Median affinity
- 9.4
- Affinity units
- pKi
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- AT2 receptor
- Gene symbol
- AGTR2
- Protein identifier
- P50052
- Median affinity
- 4.8
- Affinity units
- pEC50
Investigated indications
- Condition
- Pre-Eclampsia
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000668
- Subject identifier
- D011225
- Condition identifier
- EFO_0000668
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001461
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005081
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05937841
- NCT06157580
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 90.29
- Calculated partition coefficient (ALogP)
- 5.07
- Calculated partition coefficient (XLogP)
- 5.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 10
- Heavy atoms
- 32
- Molecular formula
- C23H29N3O4S2
- Monoisotopic mass
- 475.15994876
- Natural product
- No
- Recorded assays
- 161
- Active assays
- 37
- Confirmatory
- Other
- Screening
- Anti-Inflammatory Agents
Related records
Trials (11)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
- A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
- A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
- Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
- Cold Challenge With C21 in RP
- Effect of C21 on Forearm Blood Flow
- Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
- Safety and Efficacy of C21 in Subjects With COVID-19
- Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
- Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
- Sex Differences in the Dilatory Response of Compound 21
In development for (2)
- COVID-19 Phase 3
- Preeclampsia Early phase 1